APO-Bortezomib bortezomib 3.5mg powder for injection vial

Țară: Australia

Limbă: engleză

Sursă: Department of Health (Therapeutic Goods Administration)

Ingredient activ:

bortezomib, Quantity: 3.5 mg

Disponibil de la:

Arrotex Pharmaceuticals Pty Ltd

INN (nume internaţional):

Bortezomib

Forma farmaceutică:

Injection, powder for

Compoziție:

Excipient Ingredients: mannitol

Calea de administrare:

Subcutaneous, Intravenous

Unități în pachet:

1

Tip de prescriptie medicala:

(S4) Prescription Only Medicine

Indicații terapeutice:

Bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,Bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,Bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy and who have progressive disease.

Rezumat produs:

Visual Identification: White to off-white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Statutul autorizaţiei:

Licence status A

Data de autorizare:

2015-07-22